# PureTech Health plc (PRTC.L) fundamentals

Data as of 2026-09-08. LSE, United Kingdom. Sector: Healthcare / Biotechnology. Price 120p, market value 294 millionp.

## Valuation
- **P/E (trailing): n/a** (negative earnings). PureTech Health plc reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 44.3×**. Each dollar of revenue is priced at 44.3×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 1.3×**. The shares trade at 1.3× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -54.8%** (5-yr avg -0.3%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: -195.6%**. PureTech Health plc keeps -195.6% of revenue after the direct cost of what it sells, a thin margin typical of retail, distribution and commodity businesses.
- **Return on equity: -35.9%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -418.9%**. Return on all capital, debt included, is -418.9%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -10.6%**. Each dollar of assets produces -10.6% of profit.

## Growth
- **Revenue growth (1 yr): 10.2%** (3-yr 31.5%/yr, 5-yr -10.6%/yr). Revenue grew 10.2% over the last year, against -10.6% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): -335.0%**. Earnings per share fell 335.0%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.06**. Debt is 0.06 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 4.5×**. It would take 4.5 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Interest coverage: -4.3×**. Operating profit covers interest only -4.3×: fragile.
- **Current ratio: 6.59** (quick 6.59). Current assets cover the next year's liabilities 6.59 times.
- **Altman Z-score: 1.56**. A Z-score of 1.56 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. PureTech Health plc does not currently pay a dividend, but it returned 27.3% of its market value through buybacks over the last year.

## Analyst view
- **Analyst consensus: strong_buy** (4 analysts). 4 analysts cover PureTech Health plc; the consensus is strong_buy, with an average price target of 331p (+176% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 4.3%** (YTD -2.4%, 3-mo -1.9%). The shares are up 4.3% over twelve months including dividends.
- **From 52-week high: -16.4%** (14.6% above the low). Trading 16% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 51**. An RSI of 51 is neutral.
- **Beta (1 yr): 0.81** (volatility 35%). Beta of 0.81 against the FTSE All-Share: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=PRTC.L · Page: https://foliofundamentals.com/stocks/prtc.l

Not investment advice.